Verrica Pharmaceuticals (VRCA) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Verrica Pharmaceuticals (VRCA) has outperformed XBiotech (XBIT) over the past year, losing 4.4% versus a loss of 11.9%. Over five years, XBIT leads with a -82.7% price change compared with -96.9% for VRCA. Verrica Pharmaceuticals is the larger company by market cap ($70.6 million vs $69.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VRCA | XBIT |
|---|---|---|
| Share price | $4.11 | $2.29 |
| Market cap | $70.60M | $69.82M |
| 1-day change | -1.67% | +4.09% |
| YTD return | -50.54% | -4.18% |
| 1-year return | -4.42% | -11.92% |
| 5-year return | -96.92% | -82.66% |
| Forward P/E | — | 17.62 |
| EPS (TTM) | $-1.78 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.82 | $3.44 |
| 52-week low | $3.28 | $2.09 |
| Distance from 52-week high | -58.15% | -33.43% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +236.50% | — |
| Average volume | 63.33K | 39.91K |
| Shares outstanding | 17.18M | 30.49M |
| Employees | 76 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
VRCA vs XBIT FAQ
Which is bigger, Verrica Pharmaceuticals or XBiotech?
Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $70.60M compared with $69.82M for XBiotech (XBIT).
Which stock has performed better over the past year, VRCA or XBIT?
VRCA returned -4.42% over the past 12 months, compared with -11.92% for XBIT (price return, excluding dividends). Past performance does not predict future results.
Are Verrica Pharmaceuticals and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.